Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nucl Med Biol ; 36(2): 107-16, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19217522

RESUMO

INTRODUCTION: Noninvasive early detection of beta-amyloid (Abeta) plaques might be useful for the treatment of patients with Alzheimer's disease (AD). We herein describe the synthesis of (18)F-labeled benzylideneaniline derivatives using a novel labeling approach for imaging Abeta plaques in AD patients. METHODS: Benzylidenaniline derivatives were synthesized by reacting fluorobenzaldehyde and corresponding aniline derivatives. Fluorobenzaldehyde was labeled with (18)F by incubating [(18)F]fluoride with N,N,N-trimethylbenzaldehyde in the presence of tetrabutylammonium bicarbonate. In vitro binding assay, stability test and biodistribution study were performed. RESULTS: These compounds were stable at alkaline pH (pH >9); however, they were hydrolyzed rapidly at physiological pH (pH approximately 7.4). The K(i) values of amine-containing benzylideneaniline derivatives for Abeta(1-40) and Abeta(1-42) aggregates were 26-78 nM. These (18)F-labeled benzylideneaniline derivatives showed high brain uptake and rapid clearance after intravenous administration in normal mice (1.8-3.1%ID/g at 2 min and 0.1-1.2%ID/g at 30 min). The low level of bone activity at 30 min indicated that these (18)F-labeled benzylideneanilines are not prone to defluorination. Furthermore, the compounds have suitable lipophilicity - a property required to penetrate the blood-brain barrier. CONCLUSION: These results showed that the instability of these compounds could cause a higher early phase/late phase ratio due to rapid clearance in the normal brain. The findings from this study suggest that these (18)F-labeled benzylideneaniline derivatives are feasible for the imaging of Abeta plaques.


Assuntos
Doença de Alzheimer/diagnóstico por imagem , Compostos de Benzilideno/metabolismo , Radioisótopos de Flúor , Placa Amiloide/diagnóstico por imagem , Compostos Radiofarmacêuticos , Peptídeos beta-Amiloides/metabolismo , Animais , Barreira Hematoencefálica , Estabilidade de Medicamentos , Ligantes , Masculino , Camundongos , Camundongos Endogâmicos ICR , Fragmentos de Peptídeos/metabolismo , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/química , Compostos Radiofarmacêuticos/farmacocinética , Distribuição Tecidual
2.
Appl Radiat Isot ; 65(1): 64-9, 2007 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17010628

RESUMO

A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol ((188)Re-HDD/lipiodol) is in clinical study for liver cancer therapy. However, formulation of it is difficult due to highly active and unstable sulfhydryl groups. We produced new kits using diacetylated HDD (AHDD), in which sulfhydryl groups are protected. We found that AHDD kit can replace HDD kit due to an increased stability for formulation, the better radiolabeling efficiency (78%) and the equivalent biodistribution pattern in mice.


Assuntos
Óleo Iodado/síntese química , Óleo Iodado/farmacocinética , Marcação por Isótopo/instrumentação , Compostos Organometálicos/síntese química , Compostos Organometálicos/farmacocinética , Kit de Reagentes para Diagnóstico , Acetilação , Animais , Desenho de Equipamento , Análise de Falha de Equipamento , Óleo Iodado/uso terapêutico , Marcação por Isótopo/métodos , Taxa de Depuração Metabólica , Camundongos , Especificidade de Órgãos , Compostos Organometálicos/uso terapêutico , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacocinética , Compostos Radiofarmacêuticos/uso terapêutico , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...